Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK46575 in metastatic castration-resistant prostate cancer
NCT07007910Phase 1Recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HSK46575 in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Dec 2024; status: recruiting.
02
Drugs
HSK46575
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07007910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007910.